Despite the rising popularity of value assessment frameworks among decision makers in the health care industry, a recent analysis from the National Pharmaceutical Council (NPC) suggests they are “not ready for prime time.”
The analysis, which was published in Value in Health, examined how value assessment frameworks from the Institute for Clinical and Economic Review (ICER), the Innovation and Value Initiative (IVI) and the National Comprehensive Cancer Network (NCCN) have changed over the past two years.
“Done well, value assessments have the power to promote value in patient care and outcomes,” the authors write. “Done poorly, they could misinform healthcare decisions and harm patient care and outcomes.”
To read the article on Value in Health, click here.